Northbrook, Illinois Clinical Trials

A listing of Northbrook, Illinois clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 357 clinical trials
Safety Tolerability and Efficacy of Cilofexor in Non-Cirrhotic Adults With Primary Sclerosing Cholangitis

The primary objective of this study is to evaluate whether cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).

platelet count
cilofexor
fibrosis
NorthShore University Healthsystem
 (9.2 away) Contact site
  • 83 views
  • 14 Jun, 2021
  • +231 other locations
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)

Primary Objective: To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS Secondary Objective: To assess efficacy of SAR442168 compared to teriflunomide (Aubagio) on disability progression, MRI lesions, cognitive performance …

hmr1726
pregnancy test urine
contraceptive use
teriflunomide
brain lesion
Investigational Site Number 8400011
 (0.9 away) Contact site
  • 0 views
  • 10 Jun, 2021
  • +118 other locations
Study of Evobrutinib in Participants With RMS (evolutionRMS 1)

The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS).

evobrutinib
teriflunomide
aubagio
Research Site 649
 (0.9 away) Contact site
  • 0 views
  • 14 May, 2021
  • +243 other locations
Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS).

evobrutinib
teriflunomide
aubagio
Research Site 715
 (9.1 away) Contact site
  • 0 views
  • 13 Jun, 2021
  • +220 other locations
Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Rheumatoid Arthritis (RA)

Rheumatoid Arthritis (RA) is an inflammatory disease of the joints causing pain, stiffness, swelling and loss of joint function. This study evaluates how safe and effective ABBV-154 is in participants treated for moderately to severely active RA. Adverse events and change in the disease activity will be assessed. ABBV-154 is …

methotrexate
rheumatism
stiffness
antirheumatics
Clinic of Robert Hozman/Clinical Investigation Specialists /ID# 228174
 (9.2 away) Contact site
  • 0 views
  • 13 Jun, 2021
  • +255 other locations
A Study of Benralizumab in Patients With Eosinophilic Esophagitis

The aim of this Phase 3 study is to investigate the use of benralizumab as a treatment for patients with EoE. The effect of doses of benralizumab on EoE histologic signs and symptoms will be assessed over a 52-week treatment period (including a 24-week double-blind placebo-controlled treatment period and a …

Research Site
 (8.0 away) Contact site
  • 0 views
  • 02 Jun, 2021
  • +80 other locations
A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events Hospitalization and Death in Medically Ill Outpatients With Acute Symptomatic Coronavirus Disease 2019 (COVID-19) Infection

The purpose of this study is to evaluate whether rivaroxaban reduces the risk of a composite endpoint of major venous and arterial thrombotic events, all-cause hospitalization, and all-cause mortality compared with placebo in outpatients with acute, symptomatic Coronavirus Disease 2019 (COVID-19) Infection.

fever
fatigue
dyspnea
cancer
covid-19
Northshore Universite Healthsystem
 (9.1 away) Contact site
  • 0 views
  • 03 Jun, 2021
  • +15 other locations
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.

Illinois Cancer Specialists
 (8.3 away) Contact site
  • 50 views
  • 01 Apr, 2021
  • +122 other locations
Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

A Phase 3, 22-week, Multi-center, Randomized Withdrawal Study of ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure

NorthShore University Health System
 (4.9 away) Contact site
  • 11 views
  • 23 May, 2021
  • +89 other locations
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease

This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This …

Advocate Lutheran General Hospital
 (7.8 away) Contact site
  • 242 views
  • 17 Apr, 2021
  • +275 other locations